BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 25327631)

  • 1. CpG-loaded multifunctional cationic nanohydrogel particles as self-adjuvanting glycopeptide antitumor vaccines.
    Hartmann S; Nuhn L; Palitzsch B; Glaffig M; Stergiou N; Gerlitzki B; Schmitt E; Kunz H; Zentel R
    Adv Healthc Mater; 2015 Mar; 4(4):522-7. PubMed ID: 25327631
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthesis and immunological evaluation of self-assembling and self-adjuvanting tricomponent glycopeptide cancer-vaccine candidates.
    Wilkinson BL; Day S; Chapman R; Perrier S; Apostolopoulos V; Payne RJ
    Chemistry; 2012 Dec; 18(51):16540-8. PubMed ID: 23090901
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fully synthetic self-adjuvanting thioether-conjugated glycopeptide-lipopeptide antitumor vaccines for the induction of complement-dependent cytotoxicity against tumor cells.
    Cai H; Sun ZY; Huang ZH; Shi L; Zhao YF; Kunz H; Li YM
    Chemistry; 2013 Feb; 19(6):1962-70. PubMed ID: 23280874
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enhanced immunogenicity of multivalent MUC1 glycopeptide antitumour vaccines based on hyperbranched polymers.
    Glaffig M; Palitzsch B; Stergiou N; Schüll C; Strassburger D; Schmitt E; Frey H; Kunz H
    Org Biomol Chem; 2015 Oct; 13(40):10150-4. PubMed ID: 26299280
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunogenicity of a Fully Synthetic MUC1 Glycopeptide Antitumor Vaccine Enhanced by Poly(I:C) as a TLR3-Activating Adjuvant.
    Glaffig M; Stergiou N; Schmitt E; Kunz H
    ChemMedChem; 2017 May; 12(10):722-727. PubMed ID: 28440596
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Water-soluble polymers coupled with glycopeptide antigens and T-cell epitopes as potential antitumor vaccines.
    Nuhn L; Hartmann S; Palitzsch B; Gerlitzki B; Schmitt E; Zentel R; Kunz H
    Angew Chem Int Ed Engl; 2013 Sep; 52(40):10652-6. PubMed ID: 24038824
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MUC1-derived glycopeptide libraries with improved MHC anchors are strong antigens and prime mouse T cells for proliferative responses to lysates of human breast cancer tissue.
    Gad M; Jensen T; Gagne R; Komba S; Daugaard S; Kroman N; Meldal M; Werdelin O
    Eur J Immunol; 2003 Jun; 33(6):1624-32. PubMed ID: 12778480
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthetic multivalent glycopeptide-lipopeptide antitumor vaccines: impact of the cluster effect on the killing of tumor cells.
    Cai H; Sun ZY; Chen MS; Zhao YF; Kunz H; Li YM
    Angew Chem Int Ed Engl; 2014 Feb; 53(6):1699-703. PubMed ID: 24449389
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Generation of antitumor immunity by cytotoxic T lymphocyte epitope peptide vaccination, CpG-oligodeoxynucleotide adjuvant, and CTLA-4 blockade.
    Davila E; Kennedy R; Celis E
    Cancer Res; 2003 Jun; 63(12):3281-8. PubMed ID: 12810660
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Glycopeptide-functionalized gold nanoparticles for antibody induction against the tumor associated mucin-1 glycoprotein.
    Cai H; Degliangeli F; Palitzsch B; Gerlitzki B; Kunz H; Schmitt E; Fiammengo R; Westerlind U
    Bioorg Med Chem; 2016 Mar; 24(5):1132-5. PubMed ID: 26853835
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chemoenzymatically synthesized multimeric Tn/STn MUC1 glycopeptides elicit cancer-specific anti-MUC1 antibody responses and override tolerance.
    Sørensen AL; Reis CA; Tarp MA; Mandel U; Ramachandran K; Sankaranarayanan V; Schwientek T; Graham R; Taylor-Papadimitriou J; Hollingsworth MA; Burchell J; Clausen H
    Glycobiology; 2006 Feb; 16(2):96-107. PubMed ID: 16207894
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antitumor activity of a self-adjuvanting glyco-lipopeptide vaccine bearing B cell, CD4+ and CD8+ T cell epitopes.
    Bettahi I; Dasgupta G; Renaudet O; Chentoufi AA; Zhang X; Carpenter D; Yoon S; Dumy P; BenMohamed L
    Cancer Immunol Immunother; 2009 Feb; 58(2):187-200. PubMed ID: 18584174
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Adjuvant of α-Galactosylceramide Presented by Gold Nanoparticles Enhances Antitumor Immune Responses of MUC1 Antigen-Based Tumor Vaccines.
    Liu Y; Wang Z; Yu F; Li M; Zhu H; Wang K; Meng M; Zhao W
    Int J Nanomedicine; 2021; 16():403-420. PubMed ID: 33469292
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immune and anticancer responses elicited by fully synthetic aberrantly glycosylated MUC1 tripartite vaccines modified by a TLR2 or TLR9 agonist.
    Abdel-Aal AB; Lakshminarayanan V; Thompson P; Supekar N; Bradley JM; Wolfert MA; Cohen PA; Gendler SJ; Boons GJ
    Chembiochem; 2014 Jul; 15(10):1508-13. PubMed ID: 24890740
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synthesis of a Self-Adjuvanting MUC1 Vaccine via Diselenide-Selenoester Ligation-Deselenization.
    McDonald DM; Hanna CC; Ashhurst AS; Corcilius L; Byrne SN; Payne RJ
    ACS Chem Biol; 2018 Dec; 13(12):3279-3285. PubMed ID: 30359529
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Self-adjuvanting synthetic antitumor vaccines from MUC1 glycopeptides conjugated to T-cell epitopes from tetanus toxoid.
    Cai H; Chen MS; Sun ZY; Zhao YF; Kunz H; Li YM
    Angew Chem Int Ed Engl; 2013 Jun; 52(23):6106-10. PubMed ID: 23616304
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Towards a self-adjuvanting multivalent B and T cell epitope containing synthetic glycolipopeptide cancer vaccine.
    Renaudet O; BenMohamed L; Dasgupta G; Bettahi I; Dumy P
    ChemMedChem; 2008 May; 3(5):737-41. PubMed ID: 18205167
    [No Abstract]   [Full Text] [Related]  

  • 18. Towards a fully synthetic MUC1-based anticancer vaccine: efficient conjugation of glycopeptides with mono-, di-, and tetravalent lipopeptides using click chemistry.
    Cai H; Huang ZH; Shi L; Zhao YF; Kunz H; Li YM
    Chemistry; 2011 May; 17(23):6396-406. PubMed ID: 21538615
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synthetic antitumor vaccines containing MUC1 glycopeptides with two immunodominant domains-induction of a strong immune response against breast tumor tissues.
    Gaidzik N; Kaiser A; Kowalczyk D; Westerlind U; Gerlitzki B; Sinn HP; Schmitt E; Kunz H
    Angew Chem Int Ed Engl; 2011 Oct; 50(42):9977-81. PubMed ID: 21910197
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Self-adjuvanting multicomponent cancer vaccine candidates combining per-glycosylated MUC1 glycopeptides and the Toll-like receptor 2 agonist Pam3CysSer.
    Wilkinson BL; Day S; Malins LR; Apostolopoulos V; Payne RJ
    Angew Chem Int Ed Engl; 2011 Feb; 50(7):1635-9. PubMed ID: 21308921
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.